Patents by Inventor Joseph Loscalzo
Joseph Loscalzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11596605Abstract: The present application provides a method of making a particle comprising (i) obtaining a first solution comprising a negatively charged polysaccharide; (ii) obtaining a second solution comprising a positively charged polysaccharide; and (iii) mixing the first solution and the second solution to obtain a suspension comprising the particle. The present application also provides a method of making a therapeutic particle, comprising: (i) obtaining a solution comprising a therapeutic protein; (ii) obtaining a first suspension comprising the particle comprising a negatively charged polysaccharide and a positively charged polysaccharide, and (iii) mixing the solution of the therapeutic protein and the first suspension to obtain a second suspension comprising the therapeutic particle. The present application also provides particles (e.g.Type: GrantFiled: August 1, 2017Date of Patent: March 7, 2023Assignee: The Brigham and Women's Hospital, Inc.Inventors: Joseph Loscalzo, Ying-Yi Zhang
-
Publication number: 20220184020Abstract: Provided herein are methods of treating a vascular disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of a vascular disease associated polyphenol (e.g., rosmarinic acid), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of promoting or supporting vascular health in a subject, and methods of inhibiting platelet function (e.g., platelet aggregation) in a subject.Type: ApplicationFiled: December 21, 2021Publication date: June 16, 2022Inventors: Italo Faria do Valle, Albert-László Barábasi, Joseph Loscalzo, Harvey George Roweth, Michael William Malloy, Elisabeth M. Battinelli
-
Publication number: 20220165352Abstract: Methods and systems for generating drug repurposing predictions for a disease caused by a pathogen, such as a novel pathogen, are provided. A multi-modal system includes a protein-protein interaction network (PPI), a graph neural network (GNN), a diffusion module, a proximity module, and an aggregation module. The GNN is configured to predict new edges between candidate drug nodes and disease nodes in an embedded representation of the PPI to produce a decoded embedding space. The diffusion module is configured to determine a proximity distance for pairs of nodes in the PPI, and the proximity module is configured to determine a proximity distance for pairs of nodes in the PPI, each pair comprising a pathogen-protein node and a drug-protein node. A ranked list of candidate drugs predicted to be effective in treatment of the disease based on candidate drug lists generated by the other modules is generated by the aggregation module.Type: ApplicationFiled: November 24, 2021Publication date: May 26, 2022Inventors: Deisy Morselli Gysi, Albert-László Barábasi, Italo Faria do Valle, Onur Varol, Xiao Gan, Asher Ameli, Joseph Loscalzo, Marinka Zitnik
-
Publication number: 20210324058Abstract: Anti-NEDD9 antibodies and methods of making and using said antibodies.Type: ApplicationFiled: November 5, 2019Publication date: October 21, 2021Inventors: George A. Alba, Joseph Loscalzo, Bradley A. Maron
-
Publication number: 20210244668Abstract: The present application provides a method of making a particle comprising (i) obtaining a first solution comprising a negatively charged polysaccharide; (ii) obtaining a second solution comprising a positively charged polysaccharide; and (iii) mixing the first solution and the second solution to obtain a suspension comprising the particle. The present application also provides a method of making a therapeutic particle, comprising: (i) obtaining a solution comprising a therapeutic protein; (ii) obtaining a first suspension comprising the particle comprising a negatively charged polysaccharide and a positively charged polysaccharide, and (iii) mixing the solution of the therapeutic protein and the first suspension to obtain a second suspension comprising the therapeutic particle. The present application also provides particles (e.g.Type: ApplicationFiled: August 1, 2017Publication date: August 12, 2021Inventors: Joseph Loscalzo, Ying-Yi Zhang
-
Patent number: 9605047Abstract: The technology described herein is directed to agents that reduce the level of oxidant-modified ET-B Cys405, Cys403, or Cys402 and the identification and use of such agents for, e.g. to treat hypertension.Type: GrantFiled: April 3, 2013Date of Patent: March 28, 2017Assignee: The Brigham and Womens's Hospital, Inc.Inventors: Bradley Maron, Joseph Loscalzo, Jane Leopold
-
Publication number: 20150203563Abstract: The technology described herein is directed to agents that reduce the level of oxidant-modified ET-B Cys405, Cys403, or Cys402 and the identification and use of such agents for, e.g. to treat hypertension.Type: ApplicationFiled: April 3, 2013Publication date: July 23, 2015Applicant: The Brigham and Women's Hospital, Inc.Inventors: Bradley Maron, Joseph Loscalzo, Jane Leopold
-
Publication number: 20110295620Abstract: A computer-based screening instrument system and method comprising a patient interactive device coupled with a data network and an administrative server, the administrative server operatively connected to a database and a printer, wherein the administrative server is configured to serve as a screening instrument to the patient interactive device and to receive responsive information from the patient interactive device; and a triage module, wherein the screening instrument comprises a plurality of issues, an issue having a patient prompt and one or more patient selectable responses, wherein the patient interactive device, for each issue in the screening instrument, displays the related patient prompt, receive an indication of a patient selection of a related patient selectable response and transmit information representing the indication to the administrative server; wherein the administrative server receives the information and stores a patient response record comprising the information received; wherein theType: ApplicationFiled: May 27, 2011Publication date: December 1, 2011Applicant: CITY OF HOPEInventors: Matthew Joseph LOSCALZO, Karen Lynn Clark
-
Patent number: 7708989Abstract: The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 27, 2003Date of Patent: May 4, 2010Assignee: NitroMed, Inc.Inventors: Joseph Loscalzo, Joseph A. Vita, Michael D. Loberg, Manuel Worcel
-
Publication number: 20100068267Abstract: The invention provides methods of treating a cardiovascular disease comprising administering a sustained release formulation of hydralazine hydrochloride and at least one of isosorbide dinitrate and/or isosorbide mononitrate in therapeutically effective dosage of each of the aforementioned compounds.Type: ApplicationFiled: September 22, 2009Publication date: March 18, 2010Applicant: NITROMED, INC.Inventors: Joseph LOSCALZO, Joseph A. VITA, Michael D. LOBERG, Manuel WORCEL
-
Publication number: 20090226407Abstract: The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 27, 2003Publication date: September 10, 2009Inventors: Joseph Loscalzo, Joseph Vita, Michael Loberg, Manuel Worcel
-
Patent number: 7556824Abstract: The present invention provides novel transdermal patch comprising a therapeutic amount of a hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate in therapeutically effective dosage of each of the aforementioned compounds.Type: GrantFiled: October 7, 2003Date of Patent: July 7, 2009Assignee: NitroMed, Inc.Inventors: Joseph Loscalzo, Joseph A. Vita, Michael D. Loberg, Manuel Worcel
-
Patent number: 7537785Abstract: The present invention provides a composition comprising an antioxidant, and at least one of isosorbide dinitrate and isosorbide mononitrate in therapeutically effective dosage of each of the aforementioned compounds to treat cardiovascular diseases caused by nitric oxide (NO) insufficiency. The antioxidant is a hydralazine compound.Type: GrantFiled: October 20, 2003Date of Patent: May 26, 2009Assignee: NitroMed, Inc.Inventors: Joseph Loscalzo, Joseph A. Vita, Michael D. Loberg, Manuel Worcel
-
Publication number: 20080299542Abstract: The invention relates, in part, to identifying protein target(s) that undergo oxidative modification and the specific peptide sequences bearing oxidation-induced modifications.Type: ApplicationFiled: May 14, 2008Publication date: December 4, 2008Inventor: Joseph Loscalzo
-
Publication number: 20080139525Abstract: The invention relates, in part, to methods of treatment of inflammatory, autoimmune, vascular and cardiovascular conditions with a combination of a superoxide dismutase (SOD) mimetic and a selenium (Se) compound. The invention also relates to compositions comprising a SOD mimetic(s) and a Se compound.Type: ApplicationFiled: August 31, 2007Publication date: June 12, 2008Applicant: The Brigham and Women's Hospital, Inc.Inventor: Joseph Loscalzo
-
Publication number: 20070248676Abstract: The invention provides a method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device; coated per se on a surface of the medical device; directly or indirectly bound to reactive sites on a surface of the medical device; or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.Type: ApplicationFiled: June 27, 2007Publication date: October 25, 2007Applicant: NitroMed, Inc.Inventors: Jonathan Stamler, Joseph Loscalzo, John Folts
-
Patent number: 7235237Abstract: The present invention provides methods of treating or preventing vascular diseases caused by nitric oxide (NO) insufficiency. The methods encompass administering a composition comprising an antioxidant, a compound to treat cardiovascular diseases, a nitrosated compound, a compound that donates, transfers or relases NO, or is a NO synthase substrate, or endogenously stimulates NO synthesis, or stimulates levels of endothelium derived relaxing factor. In the said composition, a hydralazine compound may be an antioxidant, isosorbide mono-or dinitrate may be the compound to donate, transfer, release, or stimulate endogenous NO synthesis. The isorsorbide may also elevate endogenous levels of endotherlium-derived relaxing factor, or be a NO synthase substrate and angiotensin enzyme inhibitor may be nitrosated compound.Type: GrantFiled: May 2, 2001Date of Patent: June 26, 2007Assignee: NitroMed, Inc.Inventors: Joseph Loscalzo, Joseph A. Vita, Michael D. Loberg, Manuel Worcel
-
Patent number: 7157500Abstract: Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and S-nitroso-immunoglobulin. The invention also relates to therapeutic use of S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body.Type: GrantFiled: August 13, 2002Date of Patent: January 2, 2007Assignee: Brigham and Women's HospitalInventors: Jonathan Stamler, Joseph Loscalzo, Daniel Simon, David Singel
-
Publication number: 20060211601Abstract: Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-heme proteins, S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoproteins; and S-nitroso-immunoglobulins. The invention also relates to therapeutic use if S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body.Type: ApplicationFiled: February 8, 2006Publication date: September 21, 2006Inventors: Jonathan Stamler, Joseph Loscalzo
-
Publication number: 20060198831Abstract: Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and S-nitroso-immunoglobulin. The invention also relates to therapeutic use of S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body.Type: ApplicationFiled: May 5, 2006Publication date: September 7, 2006Applicant: Brigham and Women's HospitalInventors: Jonathan Stamler, Joseph Loscalzo, Daniel Simon, David Singel